Professor Stephen M. Jane
Chair, Scientific Advisory Committee
MBBS, PhD, FRACP, FRCPA, FAHMS
Dean, Sub-Faculty of Translational Medicine and Public Health, Monash University; Director of Research, The Alfred; Honorary Professor, Xi’an Jiaotong University
Professor Stephen Jane completed his medical degree at Monash University. He entered the physician training program at the Alfred, completing clinical/laboratory haematology and a PhD under Professor Hatem Salem, Director of the Australian Centre for Blood Diseases. He then spent five years in the United States of America, the first three as a postdoctoral fellow at the National Institute of Health in Bethesda, and the remainder on the faculty at St Jude Children’s Research Hospital in Memphis, Tennessee.
He returned to Australia in 1995 as a Wellcome Senior Research Fellow to the University of Melbourne at the Bone Marrow Research Laboratories in the Royal Melbourne Hospital. He became
Director of the laboratories in 2000, a Principal Research Fellow of the NHMRC in 2005 and a Professor of Medicine at University of Melbourne in 2006.
Professor Jane was appointed as the Head of Central Clinical School, Professor of Medicine, Monash University and Director of Research for Alfred Hospital in 2011. He is also a member of the Clinical Haematology Service. In the six years since his appointment the School has increased its competitive grant funding four-fold, and has recruited over 400 new researchers and 30 laboratory heads, including major groups in Neuroscience, Diabetes, Sexual Health, Psychiatry and Gastroenterology.
Professor Jane has a range of research interests investigating both developmental and acquired disorders of the blood and skin in mouse models. At a basic level, this involves the study of gene transcription. He has attracted over $20 million in competitive research funding and has published over 120 papers including articles in the premier journals Science, Nature Medicine and Developmental Cell. He has commercialised his research, with a drug developed out of his laboratory being sold to the pharmaceutic company Merck in 2016 for USD$500 Million in milestone based payments.